Literature DB >> 33862203

Changes in treatment of community-onset Clostridioides difficile infection after release of updated guidelines, Atlanta, Georgia, 2018.

Max W Adelman1, Dana Goodenough2, Samantha Sefton2, Carolyn Mackey2, Stepy Thomas3, Scott K Fridkin3, Michael H Woodworth4.   

Abstract

Updated Clostridioides difficile infection (CDI) guidelines published in 2018 recommend vancomycin as first-line treatment. Of 833 community-onset CDI cases in metropolitan Atlanta, Georgia in 2018, over half did not receive first-line treatment, although guideline adherence increased over the year. Second-line treatment was more common in patients treated in ambulatory settings.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clostridioides difficile infection; Guideline-adherent treatment; Metronidazole; Vancomycin

Mesh：

Substances：

Year:  2021        PMID： 33862203      PMCID： PMC8384660          DOI： 10.1016/j.anaerobe.2021.102364

Source DB:  PubMed          Journal:  Anaerobe        ISSN： 1075-9964            Impact factor:   2.837


  11 in total

1.  Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.

Authors:  Chris A Gentry; Darien L Campbell; Riley J Williams
Journal:  Int J Antimicrob Agents       Date:  2021-01-16       Impact factor: 5.283

2.  Impact of Revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America Clinical Practice Guidelines on the Treatment of Clostridium difficile Infections in the United States.

Authors:  Cornelius J Clancy; Deanna Buehrle; Michelle Vu; Marilyn M Wagener; M Hong Nguyen
Journal:  Clin Infect Dis       Date:  2021-06-01       Impact factor: 9.079

3.  Achievement of guideline-concordant care and in-hospital outcomes in patients with coronary artery disease in teaching and nonteaching hospitals: results from the Get With The Guidelines-Coronary Artery Disease program.

Authors:  Lori M Tam; Gregg C Fonarow; Deepak L Bhatt; Maria V Grau-Sepulveda; Adrian F Hernandez; Eric D Peterson; Lee H Schwamm; Robert P Giugliano
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-12-11

4.  Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.

Authors:  Stuart Johnson; Thomas J Louie; Dale N Gerding; Oliver A Cornely; Scott Chasan-Taber; David Fitts; Steven P Gelone; Colin Broom; David M Davidson
Journal:  Clin Infect Dis       Date:  2014-05-05       Impact factor: 9.079

5.  Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection.

Authors:  Vanessa W Stevens; Richard E Nelson; Elyse M Schwab-Daugherty; Karim Khader; Makoto M Jones; Kevin A Brown; Tom Greene; Lindsay D Croft; Melinda Neuhauser; Peter Glassman; Matthew Bidwell Goetz; Matthew H Samore; Michael A Rubin
Journal:  JAMA Intern Med       Date:  2017-04-01       Impact factor: 21.873

6.  Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

Authors:  Stuart H Cohen; Dale N Gerding; Stuart Johnson; Ciaran P Kelly; Vivian G Loo; L Clifford McDonald; Jacques Pepin; Mark H Wilcox
Journal:  Infect Control Hosp Epidemiol       Date:  2010-05       Impact factor: 3.254

7.  Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes.

Authors:  Alice Y Guh; Yi Mu; Lisa G Winston; Helen Johnston; Danyel Olson; Monica M Farley; Lucy E Wilson; Stacy M Holzbauer; Erin C Phipps; Ghinwa K Dumyati; Zintars G Beldavs; Marion A Kainer; Maria Karlsson; Dale N Gerding; L Clifford McDonald
Journal:  N Engl J Med       Date:  2020-04-02       Impact factor: 91.245

8.  Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.

Authors:  D G Teasley; D N Gerding; M M Olson; L R Peterson; R L Gebhard; M J Schwartz; J T Lee
Journal:  Lancet       Date:  1983-11-05       Impact factor: 79.321

9.  Changes in Prevalence of Health Care-Associated Infections in U.S. Hospitals.

Authors:  Shelley S Magill; Erin O'Leary; Sarah J Janelle; Deborah L Thompson; Ghinwa Dumyati; Joelle Nadle; Lucy E Wilson; Marion A Kainer; Ruth Lynfield; Samantha Greissman; Susan M Ray; Zintars Beldavs; Cindy Gross; Wendy Bamberg; Marla Sievers; Cathleen Concannon; Nicolai Buhr; Linn Warnke; Meghan Maloney; Valerie Ocampo; Janet Brooks; Tolulope Oyewumi; Shamima Sharmin; Katherine Richards; Jean Rainbow; Monika Samper; Emily B Hancock; Denise Leaptrot; Eileen Scalise; Farzana Badrun; Ruby Phelps; Jonathan R Edwards
Journal:  N Engl J Med       Date:  2018-11-01       Impact factor: 91.245

10.  Disparities in Receiving Guideline-Concordant Treatment for Lung Cancer in the United States.

Authors:  Erik F Blom; Kevin Ten Haaf; Douglas A Arenberg; Harry J de Koning
Journal:  Ann Am Thorac Soc       Date:  2020-02
View more
  1 in total

1.  Current Status of Opportunistic Infection in Inflammatory Bowel Disease Patients in Asia: A Questionnaire-Based Multicenter Study.

Authors:  Hong Yang; Zhihua Ran; Meng Jin; Jia-Ming Qian
Journal:  Gut Liver       Date:  2022-05-25       Impact factor: 4.321
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.